RecruitingPhase 1Phase 2NCT05312892

Sympathetic Mechanisms in Obesity-Crossover Design

Sympathetic Mechanisms in the Cardiovascular and Metabolic Alterations of Obesity, Crossover Design Study.

Sponsor

Vanderbilt University Medical Center

Enrollment

12 participants

Start Date

May 20, 2022

Study Type

INTERVENTIONAL

Conditions

Obesity Hypertension

Summary

We will study obese hypertensive subjects in a randomized, crossover study to determine if two weeks sympathetic blockade improves endogenous glucose production. Subjects will be studied on 3 different occasions after two weeks of receiving either placebo, amlodipine (vasodilator arm) or moxonidine (study arm). The order of the studies will be determined using computer-generated randomization. Patients will be blinded as to which treatment they are receiving on each day. An investigator blinded to the treatment assignment will perform the analysis of the data.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study investigates how the nervous system contributes to high blood pressure in obese individuals. Researchers will test whether medications that calm overactive nerve signals can lower blood pressure in people with obesity-related hypertension. **You may be eligible if...** - You are between 18 and 65 years old - You have high blood pressure (blood pressure over 130/85 mmHg or currently on blood pressure medication) - You have obesity (BMI of 30 or higher) **You may NOT be eligible if...** - You are pregnant or breastfeeding - You are a current smoker or have a history of heavy smoking (more than 2 packs/day) - You have a history of alcohol or drug abuse - You have type 1 diabetes - You have heart disease beyond hypertension (such as a recent heart attack, severe arrhythmia, or heart failure) - You are allergic to any of the study medications Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAmlodipine

Subjects will receive either an antihypertensive (amlodipine or moxonidine) medication or placebo for two weeks, then cross over to the second arm, and then after 2 weeks of the second drug/placebo, will be switched to the third arm.

DRUGMoxonidine

Moxonidine

DRUGPlacebo

Placebo